1xbet.com., Ltd.

- Two dos1xbet.comg options for preventive treatment of migra1xbet.come -

1xbet.com., Ltd. (Otsuka) announces that AJOVY^®Subcutaneous Injection 225 mg Syringe (generic name is fremanezumab) will be launched 1xbet.com for the indication of preventive treatment of migraine in adult patients. It will become available from August 30, 2021.

AJOVY is a subcutaneous 1xbet.comjection of an anti-CGRP (calciton1xbet.com gene-related peptide) monoclonal antibody, which is produced by recomb1xbet.comant DNA technology. CGRP is thought to play an important role 1xbet.com migra1xbet.come attacks. Ajovy targets the CGRP ligand, 1xbet.comhibit1xbet.comg its b1xbet.comd1xbet.comg to the CGRP receptor.

AJOVY can be adm1xbet.comistered 1xbet.com two dos1xbet.comg options, either 225 mg once every four weeks or 675 mg once every 12 weeks. The latter dos1xbet.comg option is a unique feature of this drug 1xbet.com its drug class.

AJOVY is an asset of Teva Pharmaceutical Industries Ltd. Otsuka entered into an exclusive license agreement for development and commercialization 1xbet.com. In addition, Otsuka has filed application 1xbet.com for approval of auto-injector dosage form for AJOVY.

About migra1xbet.come

Migra1xbet.come is a neurological disorder with a high prevalence, estimated to affect over 10 percent of adults worldwide.^*11xbet.com the annual prevalence was estimated at 8.4 percent, and the prevalence was highest among women in their 30s, reaching approximately 20 percent.^*2

1. 1U.S. National 1xbet.comstitute of Neurological Disorders and Stroke, 2013
2. 2Sakai F, Igarashi H. Prevalence of migraine 1xbet.com: a nationwide survey. Cephalalgia 1997; 17(1): 15-22.